Get started
Author

Giulia Maggioni

Observed names: G. Maggioni, Maggioni, Giulia
Observed institutions: Humanitas University, King's College London, Ministero della Salute, Fondazione Humanitas per la Ricerca, Istituti di Ricovero e Cura a Carattere Scientifico, IRCCS Humanitas Research Hospital
ORCID: 0000-0002-8652-4854
Observed ORCID: 0000-0002-8652-4854
OpenAlex ID: A5086066293
Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes
2021 · Matteo Bersanelli, Erica Travaglino, et al. · Journal of Clinical Oncology · 222
PDF
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes
2023 · Elisabetta Sauta, Marie Robin, et al. · Journal of Clinical Oncology · 122
PDF
Synthetic Data Generation by Artificial Intelligence to Accelerate Research and Precision Medicine in Hematology
2023 · Saverio D'Amico, Daniele Dall’Olio, et al. · JCO Clinical Cancer Informatics · 95
PDF
Clinical relevance of clonal hematopoiesis in persons aged ≥80 years
2021 · Marianna Rossi, Manja Meggendorfer, et al. · Blood · 70
PDF
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes
2024 · Cristina Astrid Tentori, Caterina Gregorio, et al. · Journal of Clinical Oncology · 48
A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study
2022 · Giulia Maggioni, Matteo Bersanelli, et al. · The Lancet Haematology · 34
Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes
2024 · Rami S Komrokji, Luca Lanino, et al. · The Lancet Haematology · 31
PDF
The future of research in hematology: Integration of conventional studies with real-world data and artificial intelligence
2021 · Francesco Passamonti, Giovanni Corrao, et al. · Blood Reviews · 30
MOSAIC: An Artificial Intelligence–Based Framework for Multimodal Analysis, Classification, and Personalized Prognostic Assessment in Rare Cancers
2024 · Saverio D'Amico, Lorenzo Dall’Olio, et al. · JCO Clinical Cancer Informatics · 23
Characterization and Clinical Implications of p53 Dysfunction in Patients With Myelodysplastic Syndromes
2025 · Matteo Zampini, Elena Riva, et al. · Journal of Clinical Oncology · 20
Response to luspatercept can be predicted and improves overall survival in the real‐life treatment of LR‐MDS
2025 · Angela Consagra, Luca Lanino, et al. · HemaSphere · 14
PDF
Using real-world evidence in haematology
2024 · Francesco Passamonti, Giovanni Corrao, et al. · Best Practice & Research Clinical Haematology · 9
An Artificial Intelligence-Based Federated Learning Platform to Boost Precision Medicine in Rare Hematological Diseases: An Initiative By GenoMed4all and Synthema Consortia
2024 · Gianluca Asti, Saverio D'Amico, et al. · Blood · 8
PDF
Mutations in the splicing factor SF3B1 are linked to frequent emergence of HLA-DRlow/neg monocytes in lower-risk myelodysplastic neoplasms
2024 · Susann Winter, Marie Schneider, et al. · Leukemia · 7
Molecular landscape of myelodysplastic neoplasms in disease classification and prognostication
2022 · Giulia Maggioni, Matteo G. Della Porta · Current Opinion in Hematology · 7
IPSS-M risk and specific sex-associated somatic mutations predict response to ESA therapy in LR-MDS: building a new score
2025 · Marco G. Raddi, Sophie Park, et al. · Blood · 5
A Comprehensive, Artificial Intelligence, Digital Twin Platform Based on Multimodal Real-World Data Integration for Personalized Medicine in Hematology
2024 · Saverio D'Amico, Elisabetta Sauta, et al. · Blood · 5
PDF
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndromes (MDS)
2023 · Cristina Astrid Tentori, Caterina Gregorio, et al. · Blood · 5
Molecular-Based Ecosystem to Improve Personalized Medicine in Chronic Myelomonocytic Leukemia
2026 · Luca Lanino, Anthony M. Hunter, et al. · Journal of Clinical Oncology · 4
PU.1-activated genomic regions define low-risk MDS subsets characterized by immune dysregulation and disease progression
2026 · Veronica Vallelonga, Francesco Gandolfi, et al. · Blood · 4
PDF
Clinical Text Reports to Stratify Patients Affected with Myeloid Neoplasms Using Natural Language Processing
2023 · Gianluca Asti, Elisabetta Sauta, et al. · Blood · 4
Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic Syndromes
2022 · Elisabetta Sauta, Marie Robin, et al. · Blood · 4
Validation of ICC hierarchical classification in secondary AML
2026 · Enrico Attardi, Marta Cipriani, et al. · Blood Advances · 3
PDF
Longitudinal Synthetic Data Generation by Artificial Intelligence to Accelerate Clinical and Translational Research in Breast Cancer
2025 · Elena Zazzetti, Saverio D'Amico, et al. · JCO Clinical Cancer Informatics · 3
VAE-Surv: A novel approach for genetic-based clustering and prognosis prediction in myelodysplastic syndromes
2025 · Cesare Rollo, Corrado Pancotti, et al. · Computer Methods and Programs in Biomedicine · 3
Works count: 78
Citation count: 812
H-index: 11
I10-index: 11
Year
Topic
Type